Effectiveness of the Supportive and Palliative Care Review Kit (SPARK) for Cancer Patients in the Acute Hospital
Study Details
Study Description
Brief Summary
Introduction
There is a rising need for palliative care services in Singapore due to a rapidly ageing population and an increasing incidence of cancer. Current existing resources are inadequate - novel models of care are needed to expand access to palliative care without requiring significantly more specialist palliative care manpower.
Oncologist-driven referrals to a palliative care consultation service is the norm worldwide, including Singapore. This results in variable access to palliative care due to differences in referral practices. Palliative care involvement is also often delayed. In this study, the investigators propose to test Supportive and Palliative care Review Kit (SPARK) - a novel integrated model of care in which the palliative care team co-rounds with the medical oncology team.
Specific Aims and Hypothesis
This study aims to evaluate the impact of SPARK compared to usual care. The study investigators hypothesize that SPARK will result in more advanced cancer patients having access to palliative care, and at the same time operate at lower net cost. The study investigators also hypothesize that the improved efficiency of SPARK will result in shorter hospital length of stay for stage 4 cancer patients.
Methods
A cluster randomized trial with step wedged design will be used to compare SPARK to usual care. Data will be collected on health services utilization and access to palliative care services. Net costs will also be compared between SPARK and usual care. Semi-structured interviews with patients and healthcare professionals will be used to explore differences in experiences of healthcare provision between both models of care.
Importance
Singapore has a rising prevalence of cancer patients who require palliative care input, but only a minority are able to access it at present. If the SPARK model of care proves to be a scalable and cost-effective way of expanding access to palliative care, more cancer patients can benefit from palliative care.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Cluster 1 Control: 1-4 months; SPARK intervention: 5-20 months |
Other: SPARK intervention
An integrated model of care (SPARK care) in which the palliative care team co-rounds with the medical oncology team, supporting them in their delivery of basic palliative care, seamlessly stepping in and out to deliver specialist palliative care directly to patients when needed.
|
| Experimental: Cluster 2 Control: 1-8 months; SPARK intervention: 9-20 months |
Other: SPARK intervention
An integrated model of care (SPARK care) in which the palliative care team co-rounds with the medical oncology team, supporting them in their delivery of basic palliative care, seamlessly stepping in and out to deliver specialist palliative care directly to patients when needed.
|
| Experimental: Cluster 3 Control: 1-12 months; SPARK intervention: 13-20 months |
Other: SPARK intervention
An integrated model of care (SPARK care) in which the palliative care team co-rounds with the medical oncology team, supporting them in their delivery of basic palliative care, seamlessly stepping in and out to deliver specialist palliative care directly to patients when needed.
|
| Experimental: Cluster 4 Control: 1-16 months; SPARK intervention: 17-20 months |
Other: SPARK intervention
An integrated model of care (SPARK care) in which the palliative care team co-rounds with the medical oncology team, supporting them in their delivery of basic palliative care, seamlessly stepping in and out to deliver specialist palliative care directly to patients when needed.
|
Outcome Measures
Primary Outcome Measures
- Hospital length of stay [6 months]
Dates of hospital admission and discharge will be collected to measure hospital length of stay
Secondary Outcome Measures
- Number of days from hospital discharge to hospital readmission [30 days]
Date of hospital discharge and date of subsequent hospital admission, if any, will be collected to measure this outcome
- Referral to palliative care services [6 months]
Presence of referral to hospital palliative care consult service, home hospice or other palliative care services will be recorded
Eligibility Criteria
Criteria
Inclusion Criteria:
- All patients admitted under the care of the medical oncology team in Singapore General Hospital will be included.
Exclusion Criteria:
- Patients below 21 years old.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | National Cancer Centre Singapore | Singapore | Singapore | 169610 |
Sponsors and Collaborators
- National Cancer Centre, Singapore
- Singapore General Hospital
- Duke-NUS Graduate Medical School
Investigators
None specified.Study Documents (Full-Text)
More Information
Publications
- Hui D, Bruera E. Models of integration of oncology and palliative care. Ann Palliat Med. 2015 Jul;4(3):89-98. doi: 10.3978/j.issn.2224-5820.2015.04.01. Review.
- Nickolich MS, El-Jawahri A, Temel JS, LeBlanc TW. Discussing the Evidence for Upstream Palliative Care in Improving Outcomes in Advanced Cancer. Am Soc Clin Oncol Educ Book. 2016;35:e534-8. doi: 10.14694/EDBK_159224.
- NRSMFSP17101